Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an ...

Moderna shares experienced a significant surge in trading on Thursday, posting a 5.58% gain in European markets and an impressive jump of up to 16% on the NASDAQ. This remarkable performance was ...

Last night, two purchases of Moderna’s stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel’s company, called Boston Biotech Ventures, bought 102,821 shares for an ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.